1. Avalon acquires RPM to boost AI-driven marketing strategies. 2. New subsidiary, Avalon Quantum AI, LLC, formed for the acquisition. 3. Stockholders' equity exceeds Nasdaq's $2.5 million requirement post-acquisition. 4. KetoAir™ marketing initiatives will leverage RPM's automated video platform. 5. Michael Mathews joins the Board, enhancing Avalon’s leadership expertise.
FAQ
Why Bullish?
The acquisition strengthens ALBT's market positioning, similar to past successful mergers in tech.
How important is it?
The acquisition directly impacts ALBT's operational capabilities and market presence in the AI space.
Why Long Term?
The integration of AI-driven content marketing will enhance brand visibility over time, as seen with other similar strategies.
Avalon GloboCare Acquires RPM Interactive in Strategic Move to Enhance AI Capabilities
FREEHOLD, N.J., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: ALBT), a leader in precision diagnostic consumer products, has announced its acquisition of RPM Interactive, Inc., a powerful generative artificial intelligence software company. This all-stock transaction will not only expand Avalon's capabilities in digital content creation but also address its stockholders’ equity needs for continued listing on The Nasdaq Capital Market.
Acquisition Details and Financial Implications
As detailed in the Agreement and Plan of Merger, dated December 12, 2025, RPM has merged into a newly formed subsidiary, Avalon Quantum AI, LLC. This merger involves the issuance of 19,500 shares of Series E Non-Voting Convertible Preferred Stock, which represents a purchase price of $19.5 million.
Each Series E Preferred Stock share carries a stated value of $1,000 and can be converted into common stock at a conversion price of $1.50. It is important to note that conversions are subject to shareholder approval and certain limitations, including a beneficial ownership cap of 4.99%.
Technological Advancements with Catch-Up SaaS Platform
RPM has developed a cutting-edge Software-as-a-Service (SaaS) platform named Catch-Up, which automates the creation of short-form video content. This platform intelligently sources relevant video clips, generates AI-driven commentary, and publishes polished content effortlessly across major platforms.
The marketing for this innovative platform is set to launch immediately in the new year. The Catch-Up SaaS platform will cater to various sectors, including:
- News
- Politics
- Sports
- Finance
- Entertainment
By utilizing this technology, Avalon aims to amplify its marketing for its flagship product, KetoAir™, enhancing digital engagement and revenue generation.
Strategic Vision for Growth
“The acquisition of RPM is an important strategic step for Avalon,” stated Meng Li, Avalon’s Interim Chief Executive Officer. “By integrating RPM's AI technology with our consumer health products, we expect to bolster our marketing efforts and significantly enhance our value creation strategy.”
Michael Mathews, CEO of RPM, emphasized the platform's revolutionary nature, which not only simplifies video production but also serves to enhance consumer engagement through targeted marketing strategies.
Leadership Changes and Future Initiatives
With the merger, Michael Mathews has joined Avalon’s Board of Directors, bringing over two decades of experience in technology and digital media. His prior achievements include leading Interclick to become a category leader before its acquisition by Yahoo.
“We are excited to welcome Michael to our Board,” added Meng Li. “His expertise in digital engagement aligns perfectly with our goals as we integrate advanced technologies into our growth strategy.”
Future Plans and Additional Mergers
Avalon has additional strategic maneuvers in the pipeline, including a pending merger with YOOV Group Holdings Limited, which focuses on advanced AI automation solutions. This underlines Avalon's commitment to expanding its capabilities within the healthcare and digital marketing sectors.
About Avalon GloboCare Corp. (NASDAQ: ALBT)
Avalon GloboCare Corp. specializes in the development of precision diagnostic consumer products, including the innovative KetoAir™ breathalyzer, FDA-registered for use in ketogenic health management. The company also actively pursues advancements in cellular therapy and maintains a diverse real estate portfolio.
For further information about Avalon GloboCare and its offerings, please visit www.avalon-globocare.com.